Clinical implications of low estimated protein intake in patients with heart failure.
Body mass index
Heart failure
Mortality
Obesity
Protein
Journal
Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
13
02
2022
received:
13
09
2021
accepted:
22
02
2022
pubmed:
16
4
2022
medline:
11
6
2022
entrez:
15
4
2022
Statut:
ppublish
Résumé
A higher protein intake has been associated with a higher muscle mass and lower mortality rates in the general population, but data about protein intake and survival in patients with heart failure (HF) are lacking. We studied the prevalence, predictors, and clinical outcome of estimated protein intake in 2516 patients from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) index cohort. Protein intake was calculated in spot urine samples using a validated formula [13.9 + 0.907 * body mass index (BMI) (kg/m We included 2282 HF patients (mean age 68 ± 12 years and 27% female). Lower estimated protein intake in HF patients was associated with a lower BMI, but with more signs of congestion. Mortality rate in the lowest quartile was 32%, compared with 18% in the highest quartile (P < 0.001). In a multivariable model, lower estimated protein intake was associated with a higher risk of death compared with the highest quartile [hazard ratio (HR) 1.50; 95% confidence interval (CI) 1.03-2.18, P = 0.036 for the lowest quartile and HR 1.46; 95% CI 1.00-2.18, P = 0.049 for the second quartile]. An estimated lower protein intake was associated with a lower BMI, but signs of congestion were more prevalent. A lower estimated protein intake was independently associated with a higher mortality risk.
Sections du résumé
BACKGROUND
A higher protein intake has been associated with a higher muscle mass and lower mortality rates in the general population, but data about protein intake and survival in patients with heart failure (HF) are lacking.
METHODS
We studied the prevalence, predictors, and clinical outcome of estimated protein intake in 2516 patients from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) index cohort. Protein intake was calculated in spot urine samples using a validated formula [13.9 + 0.907 * body mass index (BMI) (kg/m
RESULTS
We included 2282 HF patients (mean age 68 ± 12 years and 27% female). Lower estimated protein intake in HF patients was associated with a lower BMI, but with more signs of congestion. Mortality rate in the lowest quartile was 32%, compared with 18% in the highest quartile (P < 0.001). In a multivariable model, lower estimated protein intake was associated with a higher risk of death compared with the highest quartile [hazard ratio (HR) 1.50; 95% confidence interval (CI) 1.03-2.18, P = 0.036 for the lowest quartile and HR 1.46; 95% CI 1.00-2.18, P = 0.049 for the second quartile].
CONCLUSIONS
An estimated lower protein intake was associated with a lower BMI, but signs of congestion were more prevalent. A lower estimated protein intake was independently associated with a higher mortality risk.
Identifiants
pubmed: 35426256
doi: 10.1002/jcsm.12973
pmc: PMC9178387
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1762-1770Subventions
Organisme : Dutch Heart Foundation
ID : CVON2014-11 RECONNECT
Organisme : European Commission
ID : FP7-242209-BIOSTAT-CHF
Informations de copyright
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Références
Am Heart J. 2015 May;169(5):693-701.e3
pubmed: 25965717
JACC Heart Fail. 2018 Jun;6(6):476-486
pubmed: 29753673
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
ESC Heart Fail. 2017 Nov;4(4):492-498
pubmed: 29154428
Eur J Nutr. 2012 Mar;51(2):173-9
pubmed: 21562887
Nat Rev Cardiol. 2017 Jun;14(6):323-341
pubmed: 28436486
Clin Nutr. 2016 Feb;35(1):18-26
pubmed: 26797412
BMC Cardiovasc Disord. 2015 Oct 15;15:128
pubmed: 26471898
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Lancet. 2017 Nov 4;390(10107):2050-2062
pubmed: 28864332
J Am Heart Assoc. 2017 Aug 17;6(8):
pubmed: 28862947
World Health Organ Tech Rep Ser. 2007;(935):1-265, back cover
pubmed: 18330140
Kidney Int. 1985 Jan;27(1):58-65
pubmed: 3981873
J Cardiovasc Nurs. 2009 May-Jun;24(3):207-15
pubmed: 19390338
Eur J Heart Fail. 2017 Oct;19(10):1284-1293
pubmed: 28580625
Clin Exp Nephrol. 2016 Apr;20(2):258-64
pubmed: 26349434
Eur Heart J. 2016 Jun 1;37(21):1684-91
pubmed: 26865478
Int J Cardiol. 2017 Jun 1;236:283-289
pubmed: 28215466
J Am Med Dir Assoc. 2013 Aug;14(8):542-59
pubmed: 23867520
Circulation. 2016 Apr 26;133(17):1696-703
pubmed: 27143152
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1762-1770
pubmed: 35426256
J Am Coll Cardiol. 2018 Jan 30;71(4):386-398
pubmed: 29389354
JAMA Intern Med. 2016 Oct 01;176(10):1453-1463
pubmed: 27479196
Clin Nutr. 2014 Dec;33(6):929-36
pubmed: 24814383
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):35-42
pubmed: 21475692
Eur J Heart Fail. 2017 May;19(5):627-634
pubmed: 28247565
Nutrients. 2016 May 14;8(5):
pubmed: 27187465
Nutrients. 2017 Aug 03;9(8):
pubmed: 28771192
Eur Heart J. 2017 Jun 21;38(24):1883-1890
pubmed: 28329163
Open Heart. 2018 Jan 9;5(1):e000730
pubmed: 29344381
Eur J Heart Fail. 2016 Jun;18(6):716-26
pubmed: 27126231
Mol Cell Endocrinol. 2015 Jul 15;410:78-86
pubmed: 25843057